GlassScriptPhysician profile
Brett A Brechner
NPI 1629079108
$14,584.38
in general payments reported to CMS, 2019-2025
73 companies · $1,666 in 2025
The $1,666 reported for 2025 was more than what 93% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,658 · 2020: $1,686 · 2021: $2,702 · 2022: $2,152 · 2023: $2,139 · 2024: $1,581 · 2025: $1,666.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,386.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,386.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,371.12 | 2021-2025 | Vraylar, Ubrelvy, Qulipta |
| Astrazeneca Pharmaceuticals LP | $1,294.77 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Amgen INC. | $1,071.21 | 2019-2025 | Otezla, Repatha, Repatha |
| Novo Nordisk INC | $762.63 | 2019-2025 | Wegovy, Rybelsus |
| Otsuka America Pharmaceutical, INC. | $743.02 | 2019-2025 | Rexulti |
| Pfizer INC. | $697.20 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $640.94 | 2019-2025 | Jardiance, Synjardy |
| Lilly USA, LLC | $632.29 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Antares Pharma, INC. | $599.08 | 2019-2025 | Xyosted, Nocdurna, Tlando |
| Takeda Pharmaceuticals U.S.A., INC. | $570.56 | 2019-2023 | Gattex |
| Allergan, INC. | $490.09 | 2019-2021 | |
| Astellas Pharma US INC | $390.35 | 2019-2023 | Veozah, Myrbetriq |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $382.60 | 2022-2025 | Caplyta |
| Corium, LLC | $282.04 | 2022-2025 | Azstarys |
| Alkermes, INC. | $272.16 | 2019-2024 | Vivitrol, Vivitrol |
Show all 73 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brett Brechner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.